Earnings ·
Inventiva S.A. reported preliminary financial results for the first half of 2026, recording zero revenues compared to…
IVAInventiva S.A.
Inventiva S.A. reported preliminary financial results for the first half of 2026, recording zero revenues compared to €4.5 million in the prior year period. The company held €166.1 million in cash and cash equivalents plus €67.8 million in short-term deposits as of June 30, 2026. Net cash used in operating activities was (€48.7) million, a decrease from (€53.7) million in the same period last year, driven by an €8.8 million working capital change that partially offset increased R&D expenses of €50.1 million related to the NATiV3 Phase 3 clinical trial for MASH. Financing activities generated €50.9 million, reflecting proceeds from a June 2026 equity offering and debt financing, which were used to repay a €62 million EIB loan and repurchase warrants. The company expects its current resources to fund operations through the end of Q2 2027, or until early Q1 2028 if additional potential proceeds from Tranche C debt and warrant exercises are realized. Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis.